These effects were reproducible across multiple rodent obesity models and were significantly greater than those achieved with equivalent doses of free drugs, highlighting the advantage of targeted PPAR activation in ATMs. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.